BIO-RAD LABORATORIES -CL B (BIO.B) Fundamental Analysis & Valuation
NYSE:BIO.B • US0905721082
268.495 USD
-13.45 (-4.77%)
Last: Mar 9, 2026, 08:04 PM
This BIO.B fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
We assign a fundamental rating of 5 out of 10 to BIO.B. BIO.B was compared to 57 industry peers in the Life Sciences Tools & Services industry. BIO.B has an excellent financial health rating, but there are some minor concerns on its profitability. BIO.B is quite expensive at the moment. It does show a decent growth rate.
1. BIO.B Profitability Analysis
1.1 Basic Checks
- BIO.B had positive earnings in the past year.
- In the past year BIO.B had a positive cash flow from operations.
- The reported net income has been mixed in the past 5 years: BIO.B reported negative net income in multiple years.
- BIO.B had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- The Return On Assets of BIO.B (7.18%) is better than 84.21% of its industry peers.
- BIO.B has a better Return On Equity (10.20%) than 78.95% of its industry peers.
- The Return On Invested Capital of BIO.B (2.02%) is better than 61.40% of its industry peers.
- BIO.B had an Average Return On Invested Capital over the past 3 years of 2.32%. This is significantly below the industry average of 11.85%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.18% | ||
| ROE | 10.2% | ||
| ROIC | 2.02% |
ROA(3y)-5.9%
ROA(5y)-4.13%
ROE(3y)-8.39%
ROE(5y)-6.36%
ROIC(3y)2.32%
ROIC(5y)2.47%
1.3 Margins
- BIO.B's Profit Margin of 29.42% is amongst the best of the industry. BIO.B outperforms 96.49% of its industry peers.
- In the last couple of years the Profit Margin of BIO.B has declined.
- Looking at the Operating Margin, with a value of 10.30%, BIO.B is in the better half of the industry, outperforming 70.18% of the companies in the same industry.
- BIO.B's Operating Margin has declined in the last couple of years.
- With a decent Gross Margin value of 52.01%, BIO.B is doing good in the industry, outperforming 61.40% of the companies in the same industry.
- BIO.B's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.3% | ||
| PM (TTM) | 29.42% | ||
| GM | 52.01% |
OM growth 3Y-15.99%
OM growth 5Y-9.05%
PM growth 3YN/A
PM growth 5Y-27.79%
GM growth 3Y-2.41%
GM growth 5Y-1.64%
2. BIO.B Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BIO.B is destroying value.
- BIO.B has less shares outstanding than it did 1 year ago.
- The number of shares outstanding for BIO.B has been reduced compared to 5 years ago.
- Compared to 1 year ago, BIO.B has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 3.07 indicates that BIO.B is not in any danger for bankruptcy at the moment.
- BIO.B has a Altman-Z score of 3.07. This is in the better half of the industry: BIO.B outperforms 66.67% of its industry peers.
- BIO.B has a debt to FCF ratio of 3.21. This is a good value and a sign of high solvency as BIO.B would need 3.21 years to pay back of all of its debts.
- BIO.B has a Debt to FCF ratio of 3.21. This is amongst the best in the industry. BIO.B outperforms 82.46% of its industry peers.
- A Debt/Equity ratio of 0.16 indicates that BIO.B is not too dependend on debt financing.
- BIO.B's Debt to Equity ratio of 0.16 is in line compared to the rest of the industry. BIO.B outperforms 56.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 3.21 | ||
| Altman-Z | 3.07 |
ROIC/WACC0.19
WACC10.53%
2.3 Liquidity
- A Current Ratio of 5.62 indicates that BIO.B has no problem at all paying its short term obligations.
- BIO.B has a Current ratio of 5.62. This is amongst the best in the industry. BIO.B outperforms 82.46% of its industry peers.
- BIO.B has a Quick Ratio of 4.19. This indicates that BIO.B is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 4.19, BIO.B is in the better half of the industry, outperforming 75.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.62 | ||
| Quick Ratio | 4.19 |
3. BIO.B Growth Analysis
3.1 Past
- The earnings per share for BIO.B have decreased by -3.78% in the last year.
- BIO.B shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.19% yearly.
- BIO.B shows a small growth in Revenue. In the last year, the Revenue has grown by 0.65%.
- The Revenue has been growing slightly by 0.29% on average over the past years.
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
Revenue 1Y (TTM)0.65%
Revenue growth 3Y-2.68%
Revenue growth 5Y0.29%
Sales Q2Q%3.85%
3.2 Future
- Based on estimates for the next years, BIO.B will show a small growth in Earnings Per Share. The EPS will grow by 0.58% on average per year.
- Based on estimates for the next years, BIO.B will show a small growth in Revenue. The Revenue will grow by 2.54% on average per year.
EPS Next Y4.57%
EPS Next 2Y7.58%
EPS Next 3Y7.11%
EPS Next 5Y0.58%
Revenue Next Year1.81%
Revenue Next 2Y2.49%
Revenue Next 3Y2.54%
Revenue Next 5Y2.54%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. BIO.B Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 27.07, which means the current valuation is very expensive for BIO.B.
- BIO.B's Price/Earnings ratio is a bit cheaper when compared to the industry. BIO.B is cheaper than 64.91% of the companies in the same industry.
- BIO.B's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.25.
- Based on the Price/Forward Earnings ratio of 25.88, the valuation of BIO.B can be described as expensive.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of BIO.B indicates a somewhat cheap valuation: BIO.B is cheaper than 66.67% of the companies listed in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 24.39. BIO.B is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.07 | ||
| Fwd PE | 25.88 |
4.2 Price Multiples
- Based on the Price/Free Cash Flow ratio, BIO.B is valued cheaply inside the industry as 84.21% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.35 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BIO.B does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)5.92
PEG (5Y)N/A
EPS Next 2Y7.58%
EPS Next 3Y7.11%
5. BIO.B Dividend Analysis
5.1 Amount
- No dividends for BIO.B!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BIO.B Fundamentals: All Metrics, Ratios and Statistics
NYSE:BIO.B (3/9/2026, 8:04:00 PM)
268.495
-13.45 (-4.77%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12 2026-02-12/amc
Earnings (Next)04-29 2026-04-29/amc
Inst Owners90.44%
Inst Owner Change-2.11%
Ins Owners8.17%
Ins Owner ChangeN/A
Market Cap7.25B
Revenue(TTM)2.58B
Net Income(TTM)759.90M
Analysts76
Price Target342.51 (27.57%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.88%
Min EPS beat(2)-7.97%
Max EPS beat(2)15.74%
EPS beat(4)3
Avg EPS beat(4)23.95%
Min EPS beat(4)-7.97%
Max EPS beat(4)49.07%
EPS beat(8)7
Avg EPS beat(8)28.31%
EPS beat(12)9
Avg EPS beat(12)18.55%
EPS beat(16)11
Avg EPS beat(16)17.09%
Revenue beat(2)0
Avg Revenue beat(2)-0.54%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)-0.35%
Revenue beat(4)2
Avg Revenue beat(4)1.22%
Min Revenue beat(4)-0.73%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)0.02%
Revenue beat(12)3
Avg Revenue beat(12)-1.41%
Revenue beat(16)5
Avg Revenue beat(16)-1.09%
PT rev (1m)-5.79%
PT rev (3m)-5.79%
EPS NQ rev (1m)-20.96%
EPS NQ rev (3m)-21.27%
EPS NY rev (1m)1.2%
EPS NY rev (3m)-0.1%
Revenue NQ rev (1m)-2.46%
Revenue NQ rev (3m)-2.59%
Revenue NY rev (1m)-0.56%
Revenue NY rev (3m)-0.9%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.07 | ||
| Fwd PE | 25.88 | ||
| P/S | 2.81 | ||
| P/FCF | 19.35 | ||
| P/OCF | 13.62 | ||
| P/B | 0.97 | ||
| P/tB | 1.08 | ||
| EV/EBITDA | N/A |
EPS(TTM)9.92
EY3.69%
EPS(NY)10.37
Fwd EY3.86%
FCF(TTM)13.88
FCFY5.17%
OCF(TTM)19.72
OCFY7.34%
SpS95.71
BVpS276.16
TBVpS248.22
PEG (NY)5.92
PEG (5Y)N/A
Graham Number248.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.18% | ||
| ROE | 10.2% | ||
| ROCE | 2.65% | ||
| ROIC | 2.02% | ||
| ROICexc | 2.38% | ||
| ROICexgc | 2.62% | ||
| OM | 10.3% | ||
| PM (TTM) | 29.42% | ||
| GM | 52.01% | ||
| FCFM | 14.5% |
ROA(3y)-5.9%
ROA(5y)-4.13%
ROE(3y)-8.39%
ROE(5y)-6.36%
ROIC(3y)2.32%
ROIC(5y)2.47%
ROICexc(3y)2.76%
ROICexc(5y)2.85%
ROICexgc(3y)3.02%
ROICexgc(5y)3.08%
ROCE(3y)3.04%
ROCE(5y)3.23%
ROICexgc growth 3Y-9.86%
ROICexgc growth 5Y-2.45%
ROICexc growth 3Y-10.58%
ROICexc growth 5Y-3.39%
OM growth 3Y-15.99%
OM growth 5Y-9.05%
PM growth 3YN/A
PM growth 5Y-27.79%
GM growth 3Y-2.41%
GM growth 5Y-1.64%
F-Score5
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 3.21 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 6.1% | ||
| Interest Coverage | -5.71 | ||
| Cash Conversion | N/A | ||
| Profit Quality | 49.3% | ||
| Current Ratio | 5.62 | ||
| Quick Ratio | 4.19 | ||
| Altman-Z | 3.07 |
F-Score5
WACC10.53%
ROIC/WACC0.19
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)6.44%
Cap/Sales(5y)5.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
EPS Next Y4.57%
EPS Next 2Y7.58%
EPS Next 3Y7.11%
EPS Next 5Y0.58%
Revenue 1Y (TTM)0.65%
Revenue growth 3Y-2.68%
Revenue growth 5Y0.29%
Sales Q2Q%3.85%
Revenue Next Year1.81%
Revenue Next 2Y2.49%
Revenue Next 3Y2.54%
Revenue Next 5Y2.54%
EBIT growth 1Y-12.48%
EBIT growth 3Y-18.24%
EBIT growth 5Y-8.78%
EBIT Next Year46.85%
EBIT Next 3Y17.21%
EBIT Next 5Y9.79%
FCF growth 1Y40.72%
FCF growth 3Y66.2%
FCF growth 5Y-4.69%
OCF growth 1Y16.92%
OCF growth 3Y39.89%
OCF growth 5Y-1.87%
BIO-RAD LABORATORIES -CL B / BIO.B FAQ
What is the ChartMill fundamental rating of BIO-RAD LABORATORIES -CL B (BIO.B) stock?
ChartMill assigns a fundamental rating of 5 / 10 to BIO.B.
Can you provide the valuation status for BIO-RAD LABORATORIES -CL B?
ChartMill assigns a valuation rating of 3 / 10 to BIO-RAD LABORATORIES -CL B (BIO.B). This can be considered as Overvalued.
How profitable is BIO-RAD LABORATORIES -CL B (BIO.B) stock?
BIO-RAD LABORATORIES -CL B (BIO.B) has a profitability rating of 5 / 10.
How financially healthy is BIO-RAD LABORATORIES -CL B?
The financial health rating of BIO-RAD LABORATORIES -CL B (BIO.B) is 8 / 10.